Allogene Therapeutics (ALLO) Cash from Financing Activities (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Cash from Financing Activities data on file, last reported at $21.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 50.98% year-over-year to $21.1 million; the trailing twelve-month figure through Mar 2026 stood at $37.3 million (down 71.1% YoY), and the FY2025 full-year result was $30.2 million, down 74.15% from the prior year.
• Cash from Financing Activities improved to $21.1 million in Q1 2026, from $7.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q2 2024 to a low of $24000.0 in Q2 2022.
• A 5-year average of $15.7 million and a median of $3.2 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 99.25% in 2022 and jumped 372916.67% in 2023, its largest moves.
• Tracing ALLO's Cash from Financing Activities over 5 years: stood at $46000.0 in 2022, then jumped by 236.96% to $155000.0 in 2023, then soared by 3605.16% to $5.7 million in 2024, then surged by 36.84% to $7.9 million in 2025, then jumped by 168.76% to $21.1 million in 2026.
• Business Quant data shows ALLO's Cash from Financing Activities at $21.1 million in Q1 2026, $7.9 million in Q4 2025, and $3.2 million in Q3 2025.